Sangamo Therapeutics, Inc.
SGMO
$0.15
-$0.02-12.73%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -123.33M | -122.93M | -108.91M | -63.31M | -79.45M |
| Total Depreciation and Amortization | 6.56M | 7.60M | 7.85M | 8.08M | 8.76M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 20.74M | 22.35M | 8.96M | 9.73M | 14.13M |
| Change in Net Operating Assets | 5.70M | -4.22M | 15.94M | 9.60M | 11.93M |
| Cash from Operations | -90.34M | -97.21M | -76.16M | -35.90M | -44.63M |
| Capital Expenditure | -115.00K | -102.00K | -240.00K | -291.00K | -267.00K |
| Sale of Property, Plant, and Equipment | -- | -- | 1.48M | 1.82M | 1.95M |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 0.00 | 0.00 | 0.00 |
| Cash from Investing | -115.00K | -102.00K | 1.24M | 1.53M | 1.68M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 90.73M | 74.01M | 66.08M | 46.61M | 17.57M |
| Repurchase of Common Stock | -1.42M | -3.26M | -3.13M | -3.07M | -3.18M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 89.31M | 70.75M | 62.94M | 43.54M | 14.39M |
| Foreign Exchange rate Adjustments | 2.05M | 4.09M | 1.80M | 2.89M | -101.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 906.00K | -22.47M | -10.17M | 12.06M | -28.65M |